New Agents Emerge for Elusive NSCLC Targets

OncLive Staff
Published: Monday, Jul 22, 2019
Christine M. Lovly, MD, PhD

Christine M. Lovly, MD, PhD
Although immunotherapy has become an important modality for treating non–small cell lung cancer (NSCLC), the development of new strategies for targeting oncogenic drivers of disease in subgroups of patients is moving forward at a brisk pace.

The 2019 American Society of Clinical Oncology Annual Meeting (ASCO 2019) featured early findings for several promising novel therapies aimed at challenging less common targets in slices of the lung cancer mutation pie.

These emerging therapies and the aberrations they target include AMG 510, KRAS G12C mutations; BLU-667, RET fusions; capmatinib and tepotinib, MET exon 14 skipping mutations (METex14); and TAK-788, EGFR exon 20 insertion mutations.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication
x